AAV9 BBP-812

Gene therapy

AAspa Therapeutics

AAV9 BBP-812 is one of 3 biologic programs targeting Canavan disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Canavan DiseaseActive, not recruiting

Canavan DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Canavan Disease

#DrugCompanyPhaseTrials

Keppra

UCB

Phase 1

1 2

Rayos

RRoxane Laboratories

Phase 1

1 3

AAV9 BBP-812

AAspa Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Recruiting

Canavan Disease

NCT04998396

Clinical

Trials by Indication[1]

Canavan disease1 trial

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Recruiting·AAspa Therapeutics·Phase 1/2·NCT04998396·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAV9 BBP-812. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAV9 BBP-812 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAV9 BBP-812. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aspa Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Company: AAspa Therapeutics

AAV9 BBP-812

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Canavan disease1 trial

References

Drug Info

Quick Facts

Related News